Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$302.41
+0.3%
$302.15
$175.37
$329.87
$22.82B0.93471,655 shs524,730 shs
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$8.50
+0.1%
$8.47
$3.10
$8.50
$26.35M1.0363,470 shs5,000 shs
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
$0.70
-7.7%
$0.53
$0.32
$2.07
$42.44M2.12848,835 shs376,000 shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$1.16
$0.98
$4.95
$69.47M2.34396,682 shs296,500 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
+2.64%+0.42%-4.67%+20.03%+34.33%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.00%0.00%0.00%0.00%+27.82%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00%0.00%0.00%0.00%+82.66%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%-59.20%-99.25%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
2.7201 of 5 stars
2.54.00.00.02.01.72.5
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/AN/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
2.91
Moderate Buy$312.643.38% Upside
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest OSMT, LMNL, NEPT, AXON, and MGTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/24/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$400.00
4/11/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$330.00 ➝ $365.00
4/10/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$315.00 ➝ $400.00
3/13/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$380.00
2/29/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$296.00 ➝ $308.00
2/28/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $285.00
2/28/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$297.00 ➝ $339.00
2/28/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$285.00 ➝ $330.00
2/28/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$240.00 ➝ $315.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$1.56B14.60$3.20 per share94.54$21.51 per share14.06
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$310K85.00N/AN/A$8.97 per share0.95
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/A$1.23 per shareN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$177.88M0.00N/A1.00$1.50 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$174.23M$2.30131.4892.20N/A11.14%14.11%6.61%5/6/2024 (Confirmed)
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$380K$0.2929.31N/A248.35%-88.44%-64.15%N/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
-$76.46MN/A0.00N/AN/A-70.88%-57.27%N/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/A

Latest OSMT, LMNL, NEPT, AXON, and MGTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$0.9720N/A-$0.9720N/AN/AN/A  
2/27/2024Q4 2023
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$0.48$0.77+$0.29$0.79$418.97 million$432.14 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
N/AN/AN/AN/AN/A
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
0.42
3.00
2.66
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.02
2.78
2.78
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/A
19.49
19.49
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/A
0.43
0.42

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
4,26075.46 million71.16 millionOptionable
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
2513.10 million3.04 millionNot Optionable
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
6760.67 million51.46 millionNot Optionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
30262.59 million59.32 millionNot Optionable

OSMT, LMNL, NEPT, AXON, and MGTA Headlines

SourceHeadline
Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals Inc.
wsj.com - March 6 at 4:32 PM
RVL Pharmaceuticals PLC (RVLPQ)RVL Pharmaceuticals PLC (RVLPQ)
investing.com - December 19 at 9:08 AM
Other OTC Pharmaceuticals - SeychellesOther OTC Pharmaceuticals - Seychelles
statista.com - October 8 at 8:51 PM
Osmotica Pharmaceuticals is about to announce its earnings — heres what to expectOsmotica Pharmaceuticals is about to announce its earnings — here's what to expect
markets.businessinsider.com - August 14 at 1:21 AM
What Wall Street expects from Osmotica Pharmaceuticalss earningsWhat Wall Street expects from Osmotica Pharmaceuticals's earnings
markets.businessinsider.com - March 19 at 12:43 PM
GRO Biosciences Appoints Rakhshita Dhar to its Board of DirectorsGRO Biosciences Appoints Rakhshita Dhar to its Board of Directors
nz.finance.yahoo.com - January 19 at 9:21 PM
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceUPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
finance.yahoo.com - January 19 at 3:55 PM
Osmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol RVLPOsmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'
benzinga.com - January 19 at 10:54 AM
Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceOsmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
finance.yahoo.com - January 19 at 10:54 AM
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
finance.yahoo.com - January 18 at 7:56 AM
Fresh Insights On Osmotica Pharmaceuticals plc (OSMT)Fresh Insights On Osmotica Pharmaceuticals plc (OSMT)
stocksregister.com - January 15 at 6:25 PM
Osmotica Pharmaceuticals plc (OSMT): What Is Good About Stock?Osmotica Pharmaceuticals plc (OSMT): What Is Good About Stock?
marketingsentinel.com - January 11 at 7:36 AM
Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
finance.yahoo.com - January 6 at 9:24 AM
Boom Or Bust: What Are Osmotica Pharmaceuticals plc’s (NASDAQ:OSMT) Future Prospects?Boom Or Bust: What Are Osmotica Pharmaceuticals plc’s (NASDAQ:OSMT) Future Prospects?
marketingsentinel.com - January 1 at 10:28 AM
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) Shares Rose Recently. However, Trouble May Still Be Lurking.Osmotica Pharmaceuticals plc (NASDAQ: OSMT) Shares Rose Recently. However, Trouble May Still Be Lurking.
stocksregister.com - December 27 at 12:57 PM
Osmotica Pharmaceuticals plc (NASDAQ: OSMT): Why Investors Shouldn’t Ditch OSMT Stock In 2021Osmotica Pharmaceuticals plc (NASDAQ: OSMT): Why Investors Shouldn’t Ditch OSMT Stock In 2021
marketingsentinel.com - December 27 at 12:57 PM
Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Shares Plunged 0.00% In A Week – But Will They Keep Going Up?Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Shares Plunged 0.00% In A Week – But Will They Keep Going Up?
marketingsentinel.com - December 23 at 2:40 PM
James Schaub Is The Executive VP & COO of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) And They Just Picked Up 30% More SharesJames Schaub Is The Executive VP & COO of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) And They Just Picked Up 30% More Shares
nasdaq.com - December 22 at 2:02 PM
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceOsmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
finance.yahoo.com - December 20 at 6:40 PM
Osmotica Pharmaceuticals plc (NASDAQ: OSMT):The Stock Was Down -2.04 Percent From Its Lows On Friday, So What’s To Come?Osmotica Pharmaceuticals plc (NASDAQ: OSMT):The Stock Was Down -2.04 Percent From Its Lows On Friday, So What’s To Come?
marketingsentinel.com - December 18 at 6:32 PM
Osmotica Pharmaceuticals EPS Diluted (5 Year Growth)Osmotica Pharmaceuticals EPS Diluted (5 Year Growth)
ycharts.com - December 18 at 12:57 AM
Osmotica Pharmaceuticals plc (OSMT) Could Be Sitting On A GoldmineOsmotica Pharmaceuticals plc (OSMT) Could Be Sitting On A Goldmine
stocksregister.com - December 4 at 10:20 AM
What Analysts Were Expecting After Osmotica Pharmaceuticals plc (NASDAQ: OSMT) rose 2.76%What Analysts Were Expecting After Osmotica Pharmaceuticals plc (NASDAQ: OSMT) rose 2.76%
stocksregister.com - November 25 at 2:06 PM
The Future Of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) In 2021The Future Of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) In 2021
stocksregister.com - November 18 at 9:51 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Axon Enterprise logo

Axon Enterprise

NASDAQ:AXON
Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include axon officer safety plan; taser 10, taser7, taser X26P, taser X2, taser 7 CQ, and civilian series; cameras, such as axon body, axon flex, axon fleet, axon air, axon signal sidearm, axon signal vehicle, axon interview, and axon interview portable kit; software, including axon records, evidence, standards, commander, performance, auto-transcribe, justice, investigate, respond, and justice, my90, and redaction assistant; mobile applications, and training services, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. The company sells its products through its direct sales, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand bility to aggregate live video, data, and sensor feeds. It serves law enforcement, federal, correction, fire, EMS, campus, justice healthcare, retail, private security, and personal safety industries. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.
Liminal BioSciences logo

Liminal BioSciences

NASDAQ:LMNL
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Magenta Therapeutics logo

Magenta Therapeutics

NASDAQ:MGTA
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Neptune Wellness Solutions logo

Neptune Wellness Solutions

NASDAQ:NEPT
Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.
Osmotica Pharmaceuticals logo

Osmotica Pharmaceuticals

NASDAQ:OSMT
Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.